文献速递免疫规划传染病防控与疫情报告

单价mRNA新冠疫苗接种在奥密克戎变异株期间对免疫功能正常成人新冠相关有创机械通气和死亡的有效性——IVY网络,美国19个州,2022年2月1日至2023年1月31日

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-04-28

该病例对照分析评估了2-4剂单价mRNA新冠疫苗对免疫功能正常成人(≥18岁)新冠相关有创机械通气(IMV)和住院死亡的有效性,研究期间为2022年2月1日至2023年1月31日。结果显示,疫苗对IMV和住院死亡的有效性在≥18岁成人为62%,在≥65岁成人为69%;按末次接种后时间分层,7-179天为76%,180-364天为54%,≥365天为56%。单价mRNA新冠疫苗在奥密克戎变异株期间提供了实质性且持久的保护。

要点

  • ≥18岁成人疫苗对IMV和住院死亡有效性为62%,≥65岁为69%。
  • 末次接种后7-179天有效性76%,180-364天54%,≥365天56%。
  • 所有成人应按照推荐保持新冠疫苗接种最新状态。

核心结论

  • 单价mRNA新冠疫苗接种在奥密克戎变异株期间对成人IMV和住院死亡提供了实质性且持久的保护。
  • 所有成人应按照推荐保持新冠疫苗接种最新状态,以预防新冠相关危重结局。

研究设计与样本

  • 病例对照分析,评估2-4剂单价mRNA新冠疫苗对免疫功能正常成人(≥18岁)新冠相关IMV和住院死亡的有效性。
  • 研究期间为2022年2月1日至2023年1月31日,数据来自IVY网络美国19个州。

主要发现

  • 疫苗对IMV和住院死亡的有效性在≥18岁成人为62%,在≥65岁成人为69%。
  • 按末次接种后时间分层,疫苗有效性在7-179天为76%,180-364天为54%,≥365天为56%。

临床怎么用

  • 所有成人应按照推荐保持新冠疫苗接种最新状态,以预防新冠相关危重结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths in the United States, with approximately 75% of deaths occurring among adults aged ≥65 years (1). Data on the durability of protection provided by monovalent mRNA COVID-19 vaccination against critical outcomes of COVID-19 are limited beyond the Omicron BA.1 lineage period (December 26, 2021-March 26, 2022). In this case-control analysis, the effectiveness of 2-4 monovalent mRNA COVID-19 vaccine doses was evaluated against COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death among immunocompetent adults aged ≥18 years during February 1, 2022-January 31, 2023. Vaccine effectiveness (VE) against IMV and in-hospital death was 62% among adults aged ≥18 years and 69% among those aged ≥65 years. When stratified by time since last dose, VE was 76% at 7-179 days, 54% at 180-364 days, and 56% at ≥365 days. Monovalent mRNA COVID-19 vaccination provided substantial, durable protection against IMV and in-hospital death among adults during the Omicron variant period. All adults should remain up to date with recommended COVID-19 vaccination to prevent critical COVID-19-associated outcomes.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. DeCuir J, Surie D, Zhu Y, et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37104244. doi:10.15585/mmwr.mm7217a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。